Published in Antivir Ther on January 01, 2009
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates. PLoS One (2011) 0.81
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. Retrovirology (2012) 0.77
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
Innate sensing of HIV-infected cells. PLoS Pathog (2011) 2.22
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog (2009) 2.06
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (2002) 2.03
Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J Virol (2005) 1.92
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr (2005) 1.80
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol (2006) 1.68
Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J Virol (2007) 1.50
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol (2003) 1.46
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol (2004) 1.37
Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol (2006) 1.33
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol (2009) 1.30
Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One (2009) 1.28
Automated genome-wide visual profiling of cellular proteins involved in HIV infection. J Biomol Screen (2011) 1.26
Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol (2009) 1.21
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis (2002) 1.20
Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J Mol Biol (2007) 1.19
Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS One (2010) 1.18
Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS (2002) 1.14
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther (2004) 1.13
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol (2006) 1.13
Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J Virol (2003) 1.11
Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS (2003) 1.08
Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Antivir Ther (2006) 1.07
Hyperthermia stimulates HIV-1 replication. PLoS Pathog (2012) 1.04
Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol (2006) 1.01
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J Virol (2005) 1.01
HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores. J Virol (2012) 1.00
Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J Virol (2011) 0.99
Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. J Virol (2007) 0.98
Genetic and phenotypic features of blood and genital viral populations of clinically asymptomatic and antiretroviral-treatment-naive clade a human immunodeficiency virus type 1-infected women. J Clin Microbiol (2007) 0.96
Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology (2009) 0.94
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir Ther (2006) 0.93
Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol (2004) 0.92
Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology (2008) 0.87
Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms. J Virol (2011) 0.87
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother (2002) 0.87
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther (2004) 0.86
Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues. J Virol (2005) 0.86
Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. Retrovirology (2008) 0.86
Role of Gag in HIV Resistance to Protease Inhibitors. Viruses (2010) 0.85
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrob Agents Chemother (2008) 0.84
TIP47 is required for the production of infectious HIV-1 particles from primary macrophages. Traffic (2010) 0.84
Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1. J Virol (2005) 0.84
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). Antivir Ther (2006) 0.83
Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles. J Virol (2013) 0.83
Multidrug-resistant HIV-1 RNA and proviral DNA variants harboring new dipeptide insertions in the reverse transcriptase pol gene. J Acquir Immune Defic Syndr (2002) 0.83
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis (2005) 0.82
Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1. J Virol (2009) 0.81
Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. J Antimicrob Chemother (2013) 0.81
The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death. AIDS Res Hum Retroviruses (2004) 0.80
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results. AIDS (2007) 0.79
High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences. Retrovirology (2013) 0.78
Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene. PLoS One (2012) 0.77
Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α. PLoS One (2013) 0.76
Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. Antivir Ther (2007) 0.75
Corrigendum: Quantifying the Antiviral Effect of IFN on HIV-1 Replication in Cell Culture. Sci Rep (2015) 0.75